Table 1.

Drugs that may trigger AHA in G6PD-deficient patients

Definite risk of AHA“Possible” risk of AHAPossible association (less likely)
Antimalarial drugs   
 Dapsone-containing combinations* Chloroquine  
 Pamaquine* Quinidine  
 Primaquine* Quinine  
 Tafenoquine   
Other drugs   
 Ciprofloxacin Aspirin Chloramphenicol 
 Glibenclamide Menadiol sodium phosphate Dimercaptosuccinic acid 
 Methylthioninium chloride*,§ Sulfadiazine Glibenclamide 
 Moxifloxacin Sulfasalazine Mepacrine 
 Nalidixic acid Sulfonylureas Vitamin K analogs 
 Niridazole Tolonium chloride||  
 Nitrofurantoin*,   
 Norfloxacin   
 Ofloxacin   
 Phenazopyridine#   
 Rasburicase and pegloticase34,*   
 Sulfamethoxazole/ cotrimoxazole   
 Henna (cosmetic use)35-37    
Definite risk of AHA“Possible” risk of AHAPossible association (less likely)
Antimalarial drugs   
 Dapsone-containing combinations* Chloroquine  
 Pamaquine* Quinidine  
 Primaquine* Quinine  
 Tafenoquine   
Other drugs   
 Ciprofloxacin Aspirin Chloramphenicol 
 Glibenclamide Menadiol sodium phosphate Dimercaptosuccinic acid 
 Methylthioninium chloride*,§ Sulfadiazine Glibenclamide 
 Moxifloxacin Sulfasalazine Mepacrine 
 Nalidixic acid Sulfonylureas Vitamin K analogs 
 Niridazole Tolonium chloride||  
 Nitrofurantoin*,   
 Norfloxacin   
 Ofloxacin   
 Phenazopyridine#   
 Rasburicase and pegloticase34,*   
 Sulfamethoxazole/ cotrimoxazole   
 Henna (cosmetic use)35-37    

Modified from Table 4 of Luzzatto et al,38  where sources and additional references are given.

*

Evidence-based according to Youngster et al.39 

Acetylsalicylic acid. Like for all drugs, hemolysis is dose-related. The regimen of 75 to 100 mg per day, widely used for the prophylaxis of cardiovascular events, is safe for G6PD-deficient persons.

Glyburide.

§

Methylene blue.

||

Toluidine blue.

Furadantin.

#

Pyridium.

Close Modal

or Create an Account

Close Modal
Close Modal